Glimisave M1 750 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1 mg and Metformin 750 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving peripheral glucose uptake, and enhancing insulin sensitivity without causing significant hypoglycemia. The prolonged-release formulation ensures a steady release of active ingredients, promoting better glycemic stability and improved patient compliance through once-daily dosing. Glimisave M1 750 is recommended as an adjunct to diet and exercise to achieve optimal blood glucose levels in patients inadequately controlled on monotherapy or lifestyle modifications alone. It is essential to monitor renal function periodically due to the risk of lactic acidosis associated with Metformin, especially in patients with renal impairment. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Hypoglycemia risk is primarily attributed to Glimepiride and necessitates patient education regarding symptom recognition and appropriate management. Glimisave M1 750 Tablet PR should be prescribed and used under medical supervision with regular monitoring of blood glucose levels to ensure efficacy and safety.